Cerapedics Announces Breakthrough Technology Agreement with Premier Inc.

WESTMINSTER, Colo., Nov. 30, 2016 /PRNewswire/ -- Cerapedics, a privately-held orthobiologics company, today announced the company has been awarded a group purchasing agreement with Premier Inc., a leading healthcare improvement company, for Breakthrough Technology: Bone Tissue Synthetic Implantable Products. The new agreement allows Premier members, at their discretion, to take advantage of special pricing and terms pre-negotiated by Premier for i-FACTOR™ Peptide Enhanced Bone Graft. The contract is effective December 1, 2016.

"We are pleased to announce our new agreement with Premier because it will help us provide a growing number of surgeons with the advanced biologic they need to stimulate a natural bone healing process in patients with degenerative cervical disc disease," said Glen Kashuba, CEO of Cerapedics. "We look forward to the continued expansion of i-FACTOR Bone Graft commercialization into the new year."

i-FACTOR Bone Graft is based on synthetic small peptide (P-15) technology developed by Cerapedics to support bone growth through cell attachment and activation. Supported by Level I human clinical data, i-FACTOR Bone Graft received Premarket Approval (PMA) from the U.S. Food and Drug Administration (FDA) in November 2015.  

Premier unites an alliance of approximately 3,750 U.S. hospitals and 130,000 other provider organizations to transform healthcare. With integrated data and analytics, collaboratives, supply chain solutions, and advisory and other services, Premier enables better care and outcomes at a lower cost.

About Cerapedics

Cerapedics is an orthobiologics company focused on developing and commercializing its proprietary synthetic small peptide (P-15) technology platform. i-FACTOR Peptide Enhanced Bone Graft is the only biologic bone graft in orthopedics that incorporates a small peptide as an attachment factor to stimulate the natural bone healing process. This novel mechanism of action is designed to support safer and more predictable bone formation compared to commercially available bone growth factors. More information can be found at www.cerapedics.com.

Media contact:
Adam Daley
Berry & Company Public Relations
212-253-8881
[email protected]

SOURCE Cerapedics

Related Links

http://www.cerapedics.com